source
- Frazier Life Sciences raises over $1.1 billion for its public biotech fund, now $2.8 billion totalFrazier Life Sciences announced that its public fund has secured more than $1.1 billion in new capital, bringing the fund’s total assets to $2.8 billion. The fund, launched in 2021, targets small-…
- Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…